KANADA

EQS-News: Nextgen Food Robotics Corp Integrates Large Language Model (LLM) through GPT-3.5 into AI Food Ordering App: Lilly

Retrieved on: 
Monday, July 10, 2023
Artificial intelligence, Food industry, NEO, Language, LLM, OTC, Medical device, Online shopping, Lilly

Nextgen Food Robotics Corp Integrates Large Language Model (LLM) through GPT-3.5 into AI Food Ordering App: Lilly

Key Points: 
  • Nextgen Food Robotics Corp Integrates Large Language Model (LLM) through GPT-3.5 into AI Food Ordering App: Lilly
    The issuer is solely responsible for the content of this announcement.
  • Nextgen Food Robotics Corp Integrates Large Language Model (LLM) through GPT-3.5 into AI Food Ordering App: Lilly
    July 10, 2023 — Nextgen Food Robotics Corp (NEO: NGRB) (OTC: NGRBF) (Frankfurt: A3D48V), a leading innovator in food robotics and artificial intelligence, has reached a crucial milestone in the development of its AI food ordering app, Lilly, with the integration of the advanced Large Language Model (LLM) powered by GPT-3.5.
  • This milestone integration of LLM through GPT-3.5 into Lilly is a testament to Nextgen Food Robotics Corp's commitment to technological advancements.
  • For more information about Nextgen Food Robotics Corp and its AI food ordering app, Lilly, please visit www.nextgenai.ca.

EQS-News: DEFENCE AND VIEWPOINT WITH DENNIS QUAID JOIN FORCES TO EXPLORE BREAKTHROUGHS IN BIOTECHNOLOGY

Retrieved on: 
Tuesday, July 4, 2023
Biotechnology, Gene editing, Partnership, Health, Viewpoint, Therapy, Research, Pharmaceutical industry

Vancouver, BC, Canada, July 4, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”) a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce its collaboration with Viewpoint with Dennis Quaid.

Key Points: 
  • Vancouver, BC, Canada, July 4, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”) a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce its collaboration with Viewpoint with Dennis Quaid.
  • This exciting partnership aims to explore breakthroughs in biotechnology and highlight the transformative potential of cutting-edge therapeutics.
  • Defence Therapeutics Inc., with its commitment to advancing healthcare through groundbreaking research and development, has established itself as a frontrunner in the biotechnology industry.
  • Viewpoint with Dennis Quaid collaboration will explore various aspects of biotechnology, including the development of novel therapies, personalized medicine, gene editing, and emerging technologies.

EQS-News: Defence Therapeutics Inc.: DEFENCE PATENT PORTFOLIO AT THE FOREFRONT OF SUCCESS 

Retrieved on: 
Wednesday, June 28, 2023
Lymphoma, CRISPR, Intellectual property, Cell death, Therapy, Gel, Administration, SARS-CoV-2, Biotechnology, Survival, ARM, Infection, Research, Cell, RNA, Antibody, PCT, USD, Microsoft Exchange Server, Solvent, MSC, Patent, Patient, Polynucleotide phosphorylase, Reactive oxygen species, Apoptosis, Cancer, ADC, Neoplasm, Spacecraft, A-DNA, A1, Vaccine, Fine chemical, Pharmaceutical industry, Defense

Vancouver, BC, Canada, June 28, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”) is a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies.

Key Points: 
  • Vancouver, BC, Canada, June 28, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”) is a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies.
  • Sitting at the core of its innovative technologies is the proprietary AccumTM-based platform, which Defence is harnessing to develop innovative therapeutics and prophylactics against cancers and infectious diseases.
  • In lockstep with each innovation has been Defence’s aggressive pursuit of patent protection.
  • To date, seven distinct patent families relating to four different central functions of Accum™ have been published, which are highlighted below.